4.8 Article

Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53

Journal

ONCOGENE
Volume 29, Issue 3, Pages 421-431

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2009.326

Keywords

U19/EAF2; prostate cancer; tumor suppressor; TSP-1; p53

Funding

  1. NIH [R01 CA 120386, R37 DK51993]
  2. Prostate Cancer Specialized Program of Research Excellence (SPORE) [P50 CA90386]

Ask authors/readers for more resources

Inactivation of U19/EAF2 has been shown previously to lead to tumorigenesis in multiple organs; however, the mechanism of U19/EAF2 tumor suppression remains unclear. In this paper, we report that the expression of an anti-angiogenic protein, thrombospondin-1 (TSP-1) is down-regulated in the prostate and liver of U19/EAF2 knockout mouse. The U19/EAF2 knockout liver displayed increased CD31-positive blood vessels, suggesting that the TSP-1 down-regulation can contribute to increased angiogenesis. TSP-1 is reported to be a p53-target gene and p53 is a known binding partner of ELL, which binds to U19/EAF2. Here, we show that U19/EAF2 can co-localize and co-immunoprecipitate with p53 in transfected cells. In a TSP-1 promoter-driven luciferase reporter assay, p53 transfection suppressed the TSP-1 promoter activity and U19/EAF2 co-transfection blocked the p53 suppression of TSP-1 promoter. However, U19/EAF2 transfection alone had little or no effect on the TSP-1 promoter. The above observations together suggest that U19/EAF2 regulates the expression of TSP-1 via blocking p53 repression of the TSP-1 promoter. Oncogene (2010) 29, 421-431; doi:10.1038/onc.2009.326; published online 12 October 2009

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available